Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Pancreatic neuroendocrine carcinoma (p-NEC) with liver metastasis has a poor prognosis. The treatment is mainly chemotherapy which is now still a huge challenge on NEC with high ki-67 index.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Bai J
Keywords: Pancreatic neuroendocrine carcinoma, chemotherapy, Doxorubicin+mitomycin+loplatin, patient-derived tumor xenograft, Carbon ion,
Introduction: MCC is a rare and aggressive skin cancer with a neuroendocrine phenotype.Association between MCC and Polyomavirus is known.PD-1 and PD-L1 have recently become key players in the therapeutic landscape.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Birocco N
Authors: Mecca C, Maletta F, Caliendo V, Birocco N, Metovic J,
Keywords: merkel cell carcinoma, microenvironment, polyomavirus,
Introduction: Neuroendocrine neoplasms (NENs) are a series of disease which show highly heterogeneity but have limited treatment options. Previous studies showed that tumor mutation burden (TMB) in NEC was relatively high which is considered as a predictive marker of anti-PD-1 antibody.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Xu J
Authors: Jia R, Li Y, Jin Y, Chen Y, Zhang Y,
Keywords: NEC, checkpoint blockade, anti-PD-1 antibody, NENs,
Introduction: Monoclonal antibody (mAb) inhibitors of immune checkpoints, including anti–PD-1 and anti–PD-L1, have become established treatment options in various solid tumors. However, there is a paucity of data on treatment effect of checkpoint inhibition in neuroendocrine tumors (NET) and neuroendocrine carcinoma (NEC). PDR001 is a high-affinity, humanized IgG4 mAb directed against PD-1 that blocks the binding of PD-L1 and PD-L2 to PD-1.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Yao J, Fazio N, Li D, Pavel M, Strosberg J,
Keywords: PDR001, immunotherapy, NET,
Introduction: Immuno check-point inhibitors development in grade 1-2 NENs is limited by low mutation tumor load and PD-1/PDL-1 expression. The combination of an PDL-1 and CTLA-4 inhibitors could increase the probability of success in this setting. In high grade NENs the rational for immunotherapy is stronger based on experiences in small cell lung cancer.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Hernando-Cubero J
Authors: Hernando-Cubero J, Manzano J, Benavent M, Lopez C, Teulé R,
Keywords: Durvalumab, Tremelimumab, Neuroendocrine, Immunotherapy,